Fidelity Investments Portfolio holdings
Fidelity Investments, founded in 1946 by Edward C. Johnson II and headquartered in Boston, Massachusetts, is one of the largest privately-held financial services firms in the world, managing hundreds of billions in assets. Known for its wide array of investment products, including mutual funds, retirement accounts, brokerage services, and wealth management, Fidelity caters to both individual investors and institutions with a reputation for strong customer service and innovative tools like its active trader platforms. The company pioneered direct-to-investor mutual fund sales, bypassing traditional brokers, and has since expanded into areas like cryptocurrency trading and commission-free stock trades. Still family-controlled by the Johnson family, Fidelity blends a legacy of traditional investing with a forward-looking approach to technology and market trends.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPCX
SpaceX
SPCX
|
+$51.4B |
| 2 |
Broadcom
AVGO
|
+$8.12B |
| 3 |
NVIDIA
NVDA
|
+$6.62B |
| 4 |
UnitedHealth
UNH
|
+$5.92B |
| 5 |
Apple
AAPL
|
+$5.12B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Marvell Technology
MRVL
|
+$14.9B |
| 2 |
Meta Platforms (Facebook)
META
|
+$12.7B |
| 3 |
SNDK
Sandisk
SNDK
|
+$7.89B |
| 4 |
Netflix
NFLX
|
+$6.05B |
| 5 |
Coherent
COHR
|
+$4.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.62% |
| 2 | Industrials | 10.81% |
| 3 | Communication Services | 9.9% |
| 4 | Healthcare | 9.29% |
| 5 | Financials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
751
Viridian Therapeutics
VRDN
$2.47B
| $305M | 0.01% |
16,604,740
+1,225,363
| +8% | +$19.7M |
|
752
Amylyx Pharmaceuticals
AMLX
$3.69B
| $300M | 0.01% |
16,727,909
+97,368
| +0.6% | +$1.51M |
|
753
Steven Madden
SHOO
$2.96B
| $300M | 0.01% |
7,118,821
-882,097
| -11% | -$35.7M |
|
754
Hayward Holdings
HAYW
$2.7B
| $299M | 0.01% |
17,269,632
+8,618,841
| +100% | +$126M |
|
|
RAPP
755
Rapport Therapeutics
RAPP
$2.05B
| $299M | 0.01% |
7,172,894
+3,955
| +0.1% | +$145K |
|
756
CubeSmart
CUBE
$8.99B
| $299M | 0.01% |
7,515,446
+112,088
| +2% | +$4.46M |
|
757
Itaú Unibanco
ITUB
$91B
| $299M | 0.01% |
36,560,228
-9,603,665
| -21% | -$79.6M |
|
758
Maximus
MMS
$3.05B
| $298M | 0.01% |
5,544,432
-2,633,941
| -32% | -$164M |
|
759
IAMGOLD
IAG
$11.2B
| $298M | 0.01% |
18,760,673
-12,596,959
| -40% | -$220M |
|
|
FIGR
760
Figure Technology Solutions
FIGR
$7.47B
| $297M | 0.01% |
9,686,887
-3,120,650
| -24% | -$104M |
|
761
Lloyds Banking Group
LYG
$84.9B
| $297M | 0.01% |
51,014,992
+2,495,732
| +5% | +$13.5M |
|
762
Nuvation Bio
NUVB
$2.04B
| $297M | 0.01% |
52,230,295
+240,702
| +0.5% | +$1.18M |
|
763
Quest Diagnostics
DGX
$27.3B
| $296M | 0.01% |
1,398,735
+456,517
| +48% | +$89.6M |
|
764
CG Oncology
CGON
$6.43B
| $296M | 0.01% |
4,161,493
+396,649
| +11% | +$25.9M |
|
765
Snap
SNAP
$9.86B
| $295M | 0.01% |
66,514,779
-22,227,227
| -25% | -$122M |
|
766
Absci
ABSI
$1.36B
| $295M | 0.01% |
25,410,048
+2,859,051
| +13% | +$16.1M |
|
|
MBX
767
MBX Biosciences
MBX
$2.94B
| $294M | 0.01% |
5,322,885
+2,386,201
| +81% | +$83.3M |
|
768
Grand Canyon Education
LOPE
$4B
| $293M | 0.01% |
2,045,279
-637,031
| -24% | -$101M |
|
769
Weatherford International
WFRD
$6.11B
| $292M | 0.01% |
3,588,433
+20,761
| +0.6% | +$2.11M |
|
770
CME Group
CME
$98.9B
| $292M | 0.01% |
1,323,029
-2,437,877
| -65% | -$674M |
|
771
iShares MSCI Intl Value Factor ETF
IVLU
$4.64B
| $292M | 0.01% |
6,983,481
+799
| +0% | +$33.5K |
|
|
BELFB
772
Bel Fuse Inc Class B
BELFB
$3.35B
| $292M | 0.01% |
876,104
+244,797
| +39% | +$66.1M |
|
773
Corcept Therapeutics
CORT
$12B
| $290M | 0.01% |
3,337,618
+147,426
| +5% | +$8.9M |
|
774
JFrog
FROG
$11.7B
| $290M | 0.01% |
3,187,653
+951,692
| +43% | +$61.8M |
|
775
Axos Financial
AX
$5.26B
| $289M | 0.01% |
2,969,246
+531,572
| +22% | +$47.9M |
|
Similar funds
Fidelity Investments's Q2 2026 Portfolio in Review
As of Q2 2026, Fidelity Investments held 5,773 positions worth $2.3T, up 21% from $1.9T the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Fidelity Investments's Q2 2026 filing shows 351 new, 2,921 increased, 1,859 reduced and 211 closed positions. Its largest new stake was SpaceX: 302,555,831 shares worth $51.7B. The largest sale was Marvell Technology, an estimated $14.9B.
By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 32% a quarter earlier, followed by Industrials and Communication Services.
- Fidelity Investments's largest Q2 2026 buy was SpaceX: 302,555,831 shares worth $51.7B.
- Fidelity Investments added most to Broadcom in Q2 2026, an estimated $8.12B increase.
- Fidelity Investments's biggest Q2 2026 reduction was Marvell Technology, cutting an estimated $14.9B.
- Fidelity Investments fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $272M.
- Fidelity Investments's ten largest holdings make up 34% of its $2.3T portfolio in Q2 2026.
- Fidelity Investments opened 351 new positions and closed 211 in Q2 2026.
- Fidelity Investments's portfolio value rose 21% quarter-over-quarter to $2.3T.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.